- Home
- INAB vs NEPH Comparison
INAB vs NEPH Comparison
Compare INAB & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- NEPH
- Stock Information
- Founded
- INAB 2016
- NEPH 1997
- Country
- INAB United States
- NEPH United States
- Employees
- INAB N/A
- NEPH N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- NEPH Medical/Dental Instruments
- Sector
- INAB Health Care
- NEPH Health Care
- Exchange
- INAB Nasdaq
- NEPH Nasdaq
- Market Cap
- INAB 14.5M
- NEPH 16.8M
- IPO Year
- INAB 2021
- NEPH 2004
- Fundamental
- Price
- INAB $0.16
- NEPH $1.90
- Analyst Decision
- INAB Strong Buy
- NEPH Buy
- Analyst Count
- INAB 2
- NEPH 1
- Target Price
- INAB $3.60
- NEPH $5.00
- AVG Volume (30 Days)
- INAB 609.1K
- NEPH 4.8K
- Earning Date
- INAB 05-07-2025
- NEPH 05-08-2025
- Dividend Yield
- INAB N/A
- NEPH N/A
- EPS Growth
- INAB N/A
- NEPH N/A
- EPS
- INAB N/A
- NEPH 0.08
- Revenue
- INAB N/A
- NEPH $15,517,000.00
- Revenue This Year
- INAB N/A
- NEPH $9.23
- Revenue Next Year
- INAB N/A
- NEPH $12.99
- P/E Ratio
- INAB N/A
- NEPH $26.68
- Revenue Growth
- INAB N/A
- NEPH 10.34
- 52 Week Low
- INAB $0.13
- NEPH $1.36
- 52 Week High
- INAB $1.74
- NEPH $2.55
- Technical
- Relative Strength Index (RSI)
- INAB 36.75
- NEPH 50.90
- Support Level
- INAB $0.15
- NEPH $1.78
- Resistance Level
- INAB $0.17
- NEPH $2.10
- Average True Range (ATR)
- INAB 0.01
- NEPH 0.15
- MACD
- INAB 0.00
- NEPH -0.01
- Stochastic Oscillator
- INAB 3.17
- NEPH 39.97
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.